Leafwell Advances Medical Cannabis as Clinically Validated Solution for Cancer-Related Symptoms and Chronic Pain, Supports Employer-Sponsored Mental Health Benefits
CHICAGO, Could 20, 2026 (GLOBE NEWSWIRE) — Leafwell, the category-defining platform for employer-sponsored medical hashish, is asking upon stakeholders throughout the self-insured ecosystem to acknowledge physician-led medical hashish as a mainstream various to high-cost care pathways for oncology, persistent ache administration, sleep problems and past. With 700,000+ sufferers served and peer-reviewed proof in hand, Leafwell delivers HIPAA-compliant doctor telehealth consultations, personalised remedy plans and ongoing scientific assist designed to enhance outcomes whereas doubtlessly decreasing healthcare spend.
“Medical hashish is medication, and through Mental Health Awareness Month, we remind healthcare choice makers that bodily well being, emotional well being and persistent illness are deeply related,” says Emily Fisher, founder and CEO, Leafwell and a two-time breast most cancers survivor. “For members residing with most cancers or debilitating persistent ache, it may be the distinction between managing their situation with dignity and biking via high-cost, high-side-effect pharmaceutical pathways. The federal recognition of hashish as having accepted medical use validates what we’ve constructed over six years—a physician-led platform that offers sufferers, employers, and healthcare leaders confidence within the science.”
Leafwell helps well being plan members managing persistent ache, behavioral well being situations, sleep problems and the unwanted side effects of oncology remedy—situations that account for a major share of employer claims spend. Peer-reviewed analysis revealed in Pharmacy discovered medically licensed hashish sufferers skilled a 35 p.c discount in emergency division visits, whereas analysis revealed in Applied Health Economics and Health Policy estimates employer adoption of medical hashish applications might save U.S. employers $29 billion yearly.
“Employers are actively searching for clinically validated options that enhance workforce well being whereas addressing rising claims prices, with oncology-related care and persistent ache administration among the many largest drivers of employer claims spend,” says Luke Macfarlan, chief working officer, Leafwell. “We’re constructing the scientific and claims-based infrastructure to indicate how physician-guided hashish remedy might help workers really feel higher, keep productive and doubtlessly keep away from higher-cost care pathways. Leafwell’s employer-sponsored profit presents a compliance-safe, data-backed various to costly pharmaceutical merchandise and therapies, giving plan sponsors a clinically grounded lever to bend the fee curve with out compromising care high quality.”
About Leafwell
Leafwell is a number one health-tech platform devoted to integrating medical hashish into mainstream healthcare. By combining a nationwide scientific community with proprietary analysis capabilities and a singular hashish profit mannequin, Leafwell offers employers and sufferers with evidence-based, clinical-first care that measurably improves outcomes and reduces prices. Based in 2019 by Emily Fisher — a 2x breast most cancers survivor — Leafwell has served greater than 700,000 sufferers, revealed 10 peer-reviewed research, and constructed the most important hashish dispensary low cost community in america. In 2026, Leafwell launched its employer-sponsored profit: a compliance-safe, data-backed various to high-cost pharmaceutical pathways for persistent ache, most cancers care, sleep problems, and psychological well being situations. Leafwell is the trusted bridge between scientific hashish and normal medical care.
Media:
Brittany Tedesco
CPR Advertising on behalf of Leafwell
btedesco@cpronline.com
201-641-1911×14
